Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ascendis Pharma Ads (ASND)

Ascendis Pharma Ads (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,259,005
  • Shares Outstanding, K 42,135
  • Annual Sales, $ 12,500 K
  • Annual Income, $ -153,640 K
  • 60-Month Beta 0.62
  • Price/Sales 339.62
  • Price/Cash Flow N/A
  • Price/Book 5.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.37
  • Number of Estimates 4
  • High Estimate -1.27
  • Low Estimate -1.46
  • Prior Year -0.94
  • Growth Rate Est. (year over year) -45.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
90.06 +11.06%
on 10/08/19
110.95 -9.85%
on 09/23/19
-3.34 (-3.23%)
since 09/17/19
3-Month
90.06 +11.06%
on 10/08/19
121.90 -17.95%
on 08/21/19
-12.74 (-11.30%)
since 07/17/19
52-Week
53.21 +88.00%
on 11/14/18
133.96 -25.33%
on 06/03/19
+35.02 (+53.88%)
since 10/17/18

Most Recent Stories

More News
Ascendis Pharma A/S Announces Upcoming Investor Presentation in October

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 100.21 (-0.86%)
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon(TM) CNP at International Skeletal Dysplasia Society Meeting

- TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial -

ASND : 100.21 (-0.86%)
Ascendis Pharma A/S Announces Three Investor Presentations in September

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 100.21 (-0.86%)
Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results

- TransCon hGH moves towards Biologics License Application submission following completion of heiGHt and fliGHt Trials -

ASND : 100.21 (-0.86%)
Ascendis Pharma A/S Announces Second Quarter 2019 Financial Results and Business Update Conference Call on August 28

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will hold a conference...

ASND : 100.21 (-0.86%)
Ascendis Pharma A/S Announces Participation in August Investor Conferences

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 100.21 (-0.86%)
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon(TM) CNP in Children with Achondroplasia

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address significant unmet medical needs, today announced the filing of an investigational...

ASND : 100.21 (-0.86%)
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon(TM) hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone

- Provides real-world experience for switching pediatric growth hormone deficiency subjects one to 17 years old from daily growth hormone to once-weekly TransCon hGH -

ASND : 100.21 (-0.86%)
Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will hold a conference...

ASND : 100.21 (-0.86%)
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technologies to address unmet medical needs, today announced that the company will participate...

ASND : 100.21 (-0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade ASND with:

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

2nd Resistance Point 102.59
1st Resistance Point 101.84
Last Price 100.21
1st Support Level 100.03
2nd Support Level 98.97

See More

52-Week High 133.96
Fibonacci 61.8% 103.11
Last Price 100.21
Fibonacci 50% 93.58
Fibonacci 38.2% 84.05
52-Week Low 53.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar